Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nasdaq Biotechnology Ishares ETF (NQ: IBB )

140.05 +2.09 (+1.51%)
Streaming Delayed Price Updated: 9:54 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nasdaq Biotechnology Ishares ETF

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Three Lessons For Investing In Biotech Companies
Many successful blockbusters started with a small trial. But you should temper your expectations until a larger, more rigorous trial is conducted. 
Via Talk Markets
The US Dollar And Long Bonds Doing The Dosey Doe
With BRICS happening ahead of Jackson Hole, it would be good to look at the technical charts on both the dollar and the long bonds. 
Via Talk Markets
5 Meme Stocks to Sell Immediately, According to AI
As we move into September, the MarketMaster AI is flashing warning signals about risky equities. Sell these meme stocks right now. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotechnology On Drugs
​​​​​​​Biotechnology has traded basically sideways since the start of 2023. 
Via Talk Markets
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
3 Top ETFs to Buy Right Now
These three exchange-traded funds could be winning plays for patient investors. 
Via The Motley Fool
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
Weight-Loss Drug Wegovy Adds Mass To Novo Nordisk's stock, Pushing Valuation Past Denmark's GDP
Via Benzinga
CPI-Market Impact Now And Later?
A discussion about inflation, bonds, calendar ranges, and places to park your money 
Via Talk Markets
Topics Bonds Economy
Exposures Debt Markets Interest Rates
Disinflation Talk Grows, Rate Hike Bets Plummet: Top 5 ETFs Rallying On CPI Miss
The disinflationary trend continued in July, even though the annual CPI inflation rate saw a slight increase from 3% to 3.2% last month, breaking a streak of 12 consecutive months of decline. 
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
5 Magnificent ETFs to Buy Hand Over Fist for the Second Half of 2023
These exchange-traded funds (ETFs) offer low or ultralow net expense ratios and are perfectly positioned to help investors grow their wealth. 
Via The Motley Fool
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
Via Benzinga
The July 6-Month Calendar Range SPY QQQ IWM TLT
Looking at the SPY chart, we have had 7 trading days above the range high. However, to date, SPY has not really taken off from that level and sits more in consolidation mode. 
Via Talk Markets
Now That The July 6-Month Calendar Range Is Set
As this week begins with a test of the July 6-month calendar range high, should that level break down, it could mean a substantially wide trading range in store for the small caps. 
Via Talk Markets
On A Winning Streak! Many Market Signs Appear More Bullish
This past week corporate earnings announcements picked up speed. You may recall that we mentioned the large money center Banks had announced the week before. If you did not read last week’s issue, you... 
Via Talk Markets
Major Sector ETFs Re-Set In July-Blueprint
Retail XRT is in a Distribution phase and has to clear the 200-WMA and calendar range high at 67.42. A move under 63.40 would be weak. 
Via Talk Markets
Playbook Revisited As UNH Beat Could Help Sagging Healthcare Stocks
Last week saw a broadening of the rally as many top sectors were up over 3%. But healthcare was among the laggards up only 0.7%. 
Via Talk Markets
Biotech Blues: Stay Balanced Through July Earnings Season
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
Moderna: Declining Performance And Relative Weakness
Moderna's value has declined by over 75% from its peak as the world moves on from the COVID-19 pandemic, leading to concerns about its investment appeal. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
3 Biotech Stocks to Avoid Like the Plague
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs. 
Via InvestorPlace
Sunnier Skies This Past Week, But Will It Last?
The stock market rallied out of a long sideway consolidation pattern and made a new year-to-date high as well as a positive 52-week period. The S&P 500 was up 1.71%, and the Nasdaq 100 was up 3.53% for... 
Via Talk Markets
Technical And Fundamental Analysis On US Oil Fund
Energy, gas, and oil are the underperformers this year and the main reason many call for deflation, recession, or at the very least, the end of accelerating inflation. 
Via Talk Markets
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
Biotech ETFs Pop On M&A Resurgence
The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A). 
Via Talk Markets
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
Healthcare Sector Update: MedTech Trending Up
Earnings from major device companies and large-cap biopharma over the next two weeks will help us ascertain risks for the market. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.